The muscle-specific ubiquitin ligase atrogin-1/MAFbx mediates statin-induced muscle toxicity.

Statins inhibit HMG-CoA reductase, a key enzyme in cholesterol synthesis, and are widely used to treat hypercholesterolemia. These drugs can lead to a number of side effects in muscle, including muscle fiber breakdown; however, the mechanisms of muscle injury by statins are poorly understood. We report that lovastatin induced the expression of atrogin-1, a key gene involved in skeletal muscle atrophy, in humans with statin myopathy, in zebrafish embryos, and in vitro in murine skeletal muscle cells. In cultured mouse myotubes, atrogin-1 induction following lovastatin treatment was accompanied by distinct morphological changes, largely absent in atrogin-1 null cells. In zebrafish embryos, lovastatin promoted muscle fiber damage, an effect that was closely mimicked by knockdown of zebrafish HMG-CoA reductase. Moreover, atrogin-1 knockdown in zebrafish embryos prevented lovastatin-induced muscle injury. Finally, overexpression of PGC-1alpha, a transcriptional coactivator that induces mitochondrial biogenesis and protects against the development of muscle atrophy, dramatically prevented lovastatin-induced muscle damage and abrogated atrogin-1 induction both in fish and in cultured mouse myotubes. Collectively, our human, animal, and in vitro findings shed light on the molecular mechanism of statin-induced myopathy and suggest that atrogin-1 may be a critical mediator of the muscle damage induced by statins.

[1]  Jeffrey S. Damrauer,et al.  Cancer cachexia is regulated by selective targeting of skeletal muscle gene products. , 2004, The Journal of clinical investigation.

[2]  Xiaohui S. Xie,et al.  Errα and Gabpa/b specify PGC-1α-dependent oxidative phosphorylation gene expression that is altered in diabetic muscle , 2004 .

[3]  Da-Zhi Wang,et al.  Atrogin-1/muscle atrophy F-box inhibits calcineurin-dependent cardiac hypertrophy by participating in an SCF ubiquitin ligase complex. , 2004, The Journal of clinical investigation.

[4]  J. Liao Isoprenoids as mediators of the biological effects of statins. , 2002, The Journal of clinical investigation.

[5]  V. Edgerton,et al.  Metabolic profiles of three fiber types of skeletal muscle in guinea pigs and rabbits. , 1972, Biochemistry.

[6]  W. H. Schaefer,et al.  Evaluation of ubiquinone concentration and mitochondrial function relative to cerivastatin-induced skeletal myopathy in rats. , 2004, Toxicology and applied pharmacology.

[7]  T. Lømo,et al.  Calcineurin controls nerve activity-dependent specification of slow skeletal muscle fibers but not muscle growth , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[8]  W. März,et al.  Risk for myopathy with statin therapy in high-risk patients. , 2003, Archives of internal medicine.

[9]  D. Wysowski,et al.  Alendronate and risedronate: reports of severe bone, joint, and muscle pain. , 2005, Archives of internal medicine.

[10]  Richard Platt,et al.  Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. , 2004, JAMA.

[11]  A. Engel,et al.  Experimental Lovastatin Myopathy , 1993, Journal of neuropathology and experimental neurology.

[12]  P. Thompson,et al.  Effect of prolonged exercise training without weight loss on high-density lipoprotein metabolism in overweight men. , 1997, Metabolism: clinical and experimental.

[13]  A. Goldberg,et al.  Atrogin-1, a muscle-specific F-box protein highly expressed during muscle atrophy , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[14]  M. Crow,et al.  The developmental program of fast myosin heavy chain expression in avian skeletal muscles. , 1986, Developmental biology.

[15]  P. Hasselgren,et al.  GSK-3beta inhibitors reduce protein degradation in muscles from septic rats and in dexamethasone-treated myotubes. , 2005, The international journal of biochemistry & cell biology.

[16]  Jiandie D. Lin,et al.  An autoregulatory loop controls peroxisome proliferator-activated receptor gamma coactivator 1alpha expression in muscle. , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[17]  Jiandie D. Lin,et al.  PGC-1α protects skeletal muscle from atrophy by suppressing FoxO3 action and atrophy-specific gene transcription , 2006, Proceedings of the National Academy of Sciences.

[18]  Ariel Rokach The acts of terrorism. , 2002, The New England journal of medicine.

[19]  U. Wisløff,et al.  Myocardial expression of Murf-1 and MAFbx after induction of chronic heart failure: Effect on myocardial contractility. , 2007, Cardiovascular research.

[20]  L. Markson,et al.  Population implications of changes in lipid management in patients with coronary heart disease. , 2004, The American journal of cardiology.

[21]  A. Russell,et al.  Endurance training in humans leads to fiber type-specific increases in levels of peroxisome proliferator-activated receptor-gamma coactivator-1 and peroxisome proliferator-activated receptor-alpha in skeletal muscle. , 2003, Diabetes.

[22]  S. Baker,et al.  Clinical perspectives of statin-induced rhabdomyolysis. , 2006, The American journal of medicine.

[23]  D J Glass,et al.  Identification of Ubiquitin Ligases Required for Skeletal Muscle Atrophy , 2001, Science.

[24]  G. Tiao,et al.  Intracellular regulation of protein degradation during sepsis is different in fast- and slow-twitch muscle. , 1997, The American journal of physiology.

[25]  Wei Wei,et al.  Dexamethasone upregulates the expression of the nuclear cofactor p300 and its interaction with C/EBPβ in cultured myotubes , 2005, Journal of cellular biochemistry.

[26]  R. Wolfram,et al.  Muscular Side Effects of Statins , 2002, Journal of cardiovascular pharmacology.

[27]  H. Pan,et al.  Comparative Pharmacokinetics and Pharmacodynamics of Pravastatin and Lovastatin , 1990, Journal of clinical pharmacology.

[28]  K. Criswell,et al.  Roles of exercise and pharmacokinetics in cerivastatin-induced skeletal muscle toxicity. , 2005, Toxicological sciences : an official journal of the Society of Toxicology.

[29]  L. Nolte,et al.  Adaptations of skeletal muscle to exercise: rapid increase in the transcriptional coactivator PGC‐1 , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[30]  E. Marshman,et al.  Abrogation of Insulin-like Growth Factor-I (IGF-I) and Insulin Action by Mevalonic Acid Depletion , 2004, Journal of Biological Chemistry.

[31]  M. Westerfield The zebrafish book : a guide for the laboratory use of zebrafish (Danio rerio) , 1995 .

[32]  D. Wagner,et al.  Genetic screens for genes controlling motor nerve-muscle development and interactions. , 2005, Developmental biology.

[33]  G. Fishman,et al.  Regulation of peroxisome proliferator-activated receptor γ coactivator 1α (PGC-1α) and mitochondrial function by MEF2 and HDAC5 , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[34]  A. M. Marsden,et al.  Statin-Induced Muscle Necrosis in the Rat: Distribution, Development, and Fibre Selectivity , 2005, Toxicologic pathology.

[35]  R. Gregg,et al.  HMG CoA reductase inhibitor-induced myotoxicity: pravastatin and lovastatin inhibit the geranylgeranylation of low-molecular-weight proteins in neonatal rat muscle cell culture. , 1997, Toxicology and applied pharmacology.

[36]  V. Sirri,et al.  Degradation of MyoD Mediated by the SCF (MAFbx) Ubiquitin Ligase* , 2005, Journal of Biological Chemistry.

[37]  Jiandie D. Lin,et al.  Transcriptional co-activator PGC-1 alpha drives the formation of slow-twitch muscle fibres. , 2002, Nature.

[38]  A. Alshekhlee,et al.  Clinical perspectives of statin-induced rhabdomyolysis. , 2007, The American journal of medicine.

[39]  Jennie Chang,et al.  Cerivastatin and reports of fatal rhabdomyolysis. , 2002, The New England journal of medicine.

[40]  N. Bresolin,et al.  Muscle coenzyme Q10 level in statin-related myopathy. , 2005, Archives of neurology.

[41]  S. Lecker,et al.  Atrophy-related ubiquitin ligases atrogin-1 and MuRF-1 are associated with uterine smooth muscle involution in the postpartum period. , 2007, American journal of physiology. Regulatory, integrative and comparative physiology.

[42]  Marco Sandri,et al.  Foxo Transcription Factors Induce the Atrophy-Related Ubiquitin Ligase Atrogin-1 and Cause Skeletal Muscle Atrophy , 2004, Cell.

[43]  S. Krähenbühl,et al.  Toxicity of statins on rat skeletal muscle mitochondria , 2006, Cellular and Molecular Life Sciences CMLS.

[44]  R. Hohl,et al.  Pharmacodynamic effects of high dose lovastatin in subjects with advanced malignancies , 2006, Cancer Chemotherapy and Pharmacology.

[45]  J. Galper,et al.  Differential sensitivity of C2-C12 striated muscle cells to lovastatin and pravastatin. , 1995, Journal of molecular and cellular cardiology.

[46]  A. Goldberg,et al.  Activation of the ATP-ubiquitin-proteasome pathway in skeletal muscle of cachectic rats bearing a hepatoma. , 1995, The American journal of physiology.

[47]  M. Westerfield,et al.  Identification of separate slow and fast muscle precursor cells in vivo, prior to somite formation. , 1996, Development.

[48]  S. Matzno,et al.  Inhibition of cholesterol biosynthesis by squalene epoxidase inhibitor avoids apoptotic cell death in L6 myoblasts. , 1997, Journal of lipid research.

[49]  F. Booth,et al.  Molecular regulation of individual skeletal muscle fibre types. , 2003, Acta physiologica Scandinavica.

[50]  R. Gregg,et al.  Inhibition of cholesterol synthesis by squalene synthase inhibitors does not induce myotoxicity in vitro. , 1997, Toxicology and applied pharmacology.

[51]  K. Akashi,et al.  Distal elements are critical for human CD34 expression in vivo. , 2002, Blood.

[52]  Jiandie D. Lin,et al.  An autoregulatory loop controls peroxisome proliferator-activated receptor γ coactivator 1α expression in muscle , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[53]  M. Tarnopolsky,et al.  Statin myopathies: pathophysiologic and clinical perspectives. , 2001, Clinical and investigative medicine. Medecine clinique et experimentale.

[54]  Jiandie D. Lin,et al.  Transcriptional co-activator PGC-1α drives the formation of slow-twitch muscle fibres , 2002, Nature.

[55]  Y. W. Chen,et al.  Early onset of inflammation and later involvement of TGFβ in Duchenne muscular dystrophy , 2005, Neurology.

[56]  A. Goldberg,et al.  Rapid disuse and denervation atrophy involve transcriptional changes similar to those of muscle wasting during systemic diseases , 2007, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[57]  Xiaohui Xie,et al.  Erralpha and Gabpa/b specify PGC-1alpha-dependent oxidative phosphorylation gene expression that is altered in diabetic muscle. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[58]  G. Wesolowski,et al.  Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[59]  A. Goldberg,et al.  IGF-I stimulates muscle growth by suppressing protein breakdown and expression of atrophy-related ubiquitin ligases, atrogin-1 and MuRF1. , 2004, American journal of physiology. Endocrinology and metabolism.

[60]  A. Goldberg,et al.  Multiple types of skeletal muscle atrophy involve a common program of changes in gene expression , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[61]  D. Unnikrishnan,et al.  Exertion-induced rhabdomyolysis in a patient on statin therapy. , 2005, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[62]  C. Kimmel,et al.  Stages of embryonic development of the zebrafish , 1995, Developmental dynamics : an official publication of the American Association of Anatomists.

[63]  Christoph Handschin,et al.  Metabolic control through the PGC-1 family of transcription coactivators. , 2005, Cell metabolism.

[64]  R. Naviaux,et al.  Statin myotoxicity is associated with changes in the cardiopulmonary function. , 2004, Atherosclerosis.

[65]  A. Goldberg,et al.  Mechanisms of muscle wasting. The role of the ubiquitin-proteasome pathway. , 1996, The New England journal of medicine.

[66]  P. Thompson,et al.  Statin-associated myopathy. , 2003, JAMA.

[67]  A. Goldberg,et al.  Effects of food deprivation on protein synthesis and degradation in rat skeletal muscles. , 1976, The American journal of physiology.

[68]  V. Sukhatme,et al.  Endostatin is a potential inhibitor of Wnt signaling , 2002, The Journal of cell biology.

[69]  G. Fishman,et al.  Regulation of peroxisome proliferator-activated receptor gamma coactivator 1 alpha (PGC-1 alpha ) and mitochondrial function by MEF2 and HDAC5. , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[70]  D. Wysowski,et al.  Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002: the importance of reporting suspected reactions. , 2005, Archives of internal medicine.

[71]  E. Bruckert,et al.  Comparison of efficacy and safety assessment of fluvastatin in patients <65 years versus > or =65 years of age. , 2005, The American journal of cardiology.

[72]  D. Attaix,et al.  Altered responses in skeletal muscle protein turnover during aging in anabolic and catabolic periods. , 2005, The international journal of biochemistry & cell biology.

[73]  M. Poot,et al.  Analysis of mitochondrial morphology and function with novel fixable fluorescent stains. , 1996, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[74]  W. Krone,et al.  Effect of Ezetimibe and/or Simvastatin on Coenzyme Q10 Levels in Plasma , 2006, Drug safety.

[75]  E. Bruckert,et al.  Mild to Moderate Muscular Symptoms with High-Dosage Statin Therapy in Hyperlipidemic Patients —The PRIMO Study , 2005, Cardiovascular Drugs and Therapy.

[76]  Statin-associated myopathy with normal creatine kinase levels. , 2003, Annals of internal medicine.

[77]  E. Boerwinkle,et al.  Ethnic and sex differences in the prevalence, treatment, and control of dyslipidemia among hypertensive adults in the GENOA study. , 2004, Archives of internal medicine.

[78]  S. Baker Molecular clues into the pathogenesis of statin‐mediated muscle toxicity , 2005, Muscle & nerve.

[79]  P. Puigserver,et al.  A Cold-Inducible Coactivator of Nuclear Receptors Linked to Adaptive Thermogenesis , 1998, Cell.

[80]  A. Butte,et al.  Coordinated reduction of genes of oxidative metabolism in humans with insulin resistance and diabetes: Potential role of PGC1 and NRF1 , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[81]  Andrew K Godwin,et al.  Response markers and the molecular mechanisms of action of Gleevec in gastrointestinal stromal tumors. , 2003, Molecular cancer therapeutics.

[82]  E. Taylor,et al.  Endurance training increases skeletal muscle LKB1 and PGC-1alpha protein abundance: effects of time and intensity. , 2005, American journal of physiology. Endocrinology and metabolism.

[83]  S. Ranganathan,et al.  The role of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity in the regulation of ubiquinone synthesis in human fibroblasts. , 1980, The Journal of biological chemistry.